alright folks....how about this one...
CytoGenix Scientists to Publish Book Chapter
Thursday August 31, 11:20 am ET
HOUSTON--(BUSINESS WIRE)--Aug. 31, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced today that its Vice President and Chief Scientific Officer, Dr. Yin Chen and Senior Scientist, Dr. Xin-Xing Tan were invited by Nova Science Publishers, New York to contribute a chapter for a soon to be published text titled "New Research on Antisense Elements (Genetics)".
ADVERTISEMENT
Dr. Chen's and Dr. Tan's contribution entitled "Oligodeoxynucleotide Expression Library for Discovery of Novel Antibiotics" is a review of the results of their work in the development of DNA compounds that are highly effective against antibacterial resistant strains.
Traditionally, most antibacterial drugs come from bacteria, fungi or other natural sources. Through natural selection, resistant strains of bacteria have developed protection mechanisms against the activity of these natural substances. Drs. Chen's and Tan's research demonstrates how genetics can be used to find gene targets that are less subject to change as the basis for developing novel DNA antimicrobial compounds.
Dr. Malcolm Skolnick, CytoGenix CEO commented, "CytoGenix is home to a cadre of scientists with skill and training in molecular and cell biology, nucleic acid chemistry and infectious diseases. This multidiscipline group has invented two innovative platform technologies and continues to investigate new product opportunities. The work reported by Drs. Yin and Tan forms the basis for an important approach to combating antibiotic resistant bacteria."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix is the recipient of the 2006 Frost & Sullivan Technology Innovation award for biotechnology processing, and has one issued US patent and 43 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
AI
